View Item 

Show simple item record

Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease
dc.contributor.authorAssassi, Shervin
dc.contributor.authorLi, Ning
dc.contributor.authorVolkmann, Elizabeth R.
dc.contributor.authorMayes, Maureen D.
dc.contributor.authorRünger, Dennis
dc.contributor.authorYing, Jun
dc.contributor.authorRoth, Michael D.
dc.contributor.authorHinchcliff, Monique
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorFrech, Tracy
dc.contributor.authorClements, Philip J.
dc.contributor.authorFurst, Daniel E.
dc.contributor.authorGoldin, Jonathan
dc.contributor.authorBernstein, Elana J.
dc.contributor.authorCastelino, Flavia V.
dc.contributor.authorDomsic, Robyn T.
dc.contributor.authorGordon, Jessica K.
dc.contributor.authorHant, Faye N.
dc.contributor.authorShah, Ami A.
dc.contributor.authorShanmugam, Victoria K.
dc.contributor.authorSteen, Virginia D.
dc.contributor.authorElashoff, Robert M.
dc.contributor.authorTashkin, Donald P.
dc.date.accessioned2021-06-02T21:06:49Z
dc.date.available2022-07-02 17:06:48en
dc.date.available2021-06-02T21:06:49Z
dc.date.issued2021-06
dc.identifier.citationAssassi, Shervin; Li, Ning; Volkmann, Elizabeth R.; Mayes, Maureen D.; Rünger, Dennis ; Ying, Jun; Roth, Michael D.; Hinchcliff, Monique; Khanna, Dinesh; Frech, Tracy; Clements, Philip J.; Furst, Daniel E.; Goldin, Jonathan; Bernstein, Elana J.; Castelino, Flavia V.; Domsic, Robyn T.; Gordon, Jessica K.; Hant, Faye N.; Shah, Ami A.; Shanmugam, Victoria K.; Steen, Virginia D.; Elashoff, Robert M.; Tashkin, Donald P. (2021). "Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease." Arthritis & Rheumatology (6): 1005-1013.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/167794
dc.publisherWiley Periodicals, Inc.
dc.titlePredictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167794/1/art41627.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167794/2/art41627_am.pdf
dc.identifier.doi10.1002/art.41627
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceBauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon‐regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.
dc.identifier.citedreferenceSteen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66: 940 – 4.
dc.identifier.citedreferenceTyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809 – 15.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma‐related interstitial lung disease (SLS II): a randomised controlled, double‐blind, parallel group trial. Lancet Respir Med 2016;​ 4: 708 – 19.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes‐Elstein L, et al. Short‐term progression of interstitial lung disease in systemic sclerosis predicts long‐term survival in two independent clinical trial cohorts. Ann Rheum Dis 2019; 78: 122 – 30.
dc.identifier.citedreferenceRadis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis: a 20‐year followup study. Arthritis Rheum 1995; 38: 1120 – 7.
dc.identifier.citedreferenceAssassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon‐mediated continuum. Arthritis Rheum 2010; 62: 589 – 98.
dc.identifier.citedreferenceTan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45: 694 – 702.
dc.identifier.citedreferenceYork MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll‐like receptor agonists. Arthritis Rheum 2007; 56: 1010 – 20.
dc.identifier.citedreferenceDuan R, Leo P, Bradbury L, Brown MA, Thomas GP. Gene expression profiling reveals a down‐regulation in immune‐associated genes in AS patients. Ann Rheum Dis 2009; 69: 1724 – 9.
dc.identifier.citedreferenceLiu X, Mayes MD, Tan FK, Wu M, Reveille JD, Harper BE, et al. Correlation of interferon‐inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 2013; 65: 226 – 35.
dc.identifier.citedreferenceAssassi S, Wang X, Chen G, Goldmuntz E, Keyes‐Elstein L, Ying J, et al. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Ann Rheum Dis 2019; 78: 1371 – 8.
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 90.
dc.identifier.citedreferenceMahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751 – 8.
dc.identifier.citedreferenceKim HJ, Li G, Gjertson D, Elashoff R, Shah SK, Ochs R, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008; 15: 1004 – 16.
dc.identifier.citedreferenceGoh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248 – 54.
dc.identifier.citedreferenceRusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferome v2.0: an updated database of annotated interferon‐regulated genes. Nucleic Acids Res 2013; 41: D1040 – 6.
dc.identifier.citedreferenceRivnak AJ, Rissin DM, Kan CW, Song L, Fishburn MW, Piech T, et al. A fully‐automated, six‐plex single molecule immunoassay for measuring cytokines in blood. J Immunol Methods 2015; 424: 20 – 7.
dc.identifier.citedreferenceDe Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40: 435 – 46.
dc.identifier.citedreferenceTaniguchi T, Miyagawa T, Toyama S, Yamashita T, Nakamura K, Saigusa R, et al. CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. Exp Dermatol 2018; 27: 1030 – 7.
dc.identifier.citedreferenceBaechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon‐inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610 – 5.
dc.identifier.citedreferenceBauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon‐regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098 – 107.
dc.identifier.citedreferenceFrech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, et al. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013; 31: 166 – 71.
dc.identifier.citedreferenceLi N, Elashoff RM, Li G. Robust joint modeling of longitudinal measurements and competing risks failure time data. Biom J 2009; 51: 19 – 30.
dc.identifier.citedreferenceBenjamimi Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995; 57: 289 – 300.
dc.identifier.citedreferenceSalazar GA, Kuwana M, Wu M, Estrada YM, Ying J, Charles J, et al. KL‐6 but not CCL‐18 is a predictor of early progression in systemic sclerosis‐related interstitial lung disease. J Rheumatol 2018; 45: 1153 – 8.
dc.identifier.citedreferenceGuo X, Higgs BW, Bay‐Jensen AC, Karsdal MA, Yao Y, Roskos LK, et al. Suppression of T cell activation and collagen accumulation by an anti‐IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. J Invest Dermatol 2015; 135: 2402 – 9.
dc.identifier.citedreferenceSkaug B, Assassi S. Type I interferon dysregulation in systemic sclerosis. Cytokine 2020; 132: 154635.
dc.identifier.citedreferenceSaigusa R, Asano Y, Taniguchi T, Yamashita T, Ichimura Y, Takahashi T, et al. Multifaceted contribution of the TLR4‐activated IRF5 transcription factor in systemic sclerosis. Proc Natl Acad Sci U S A 2015; 112: 15136 – 41.
dc.identifier.citedreferenceWu M, Skaug B, Bi X, Mills T, Salazar G, Zhou X, et al. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis. Ann Rheum Dis 2019; 78: 1583 – 91.
dc.identifier.citedreferenceBlack CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon‐α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 1999; 42: 299 – 305.
dc.identifier.citedreferenceMuangchan C, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research Group, Baron M, et al. Association of C‐reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012; 64: 1405 – 14.
dc.identifier.citedreferenceLiu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, et al. Does C‐reactive protein predict the long‐term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013; 65: 1375 – 80.
dc.identifier.citedreferenceSumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Toyama T, et al. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: a longitudinal observational study. J Dermatol 2018; 45: 1425 – 33.
dc.identifier.citedreferenceAssassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM, Draeger HT, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
dc.identifier.citedreferenceDistler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis‐associated interstitial lung disease. N Engl J Med 2019; 380: 2518 – 28.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41627.pdf
Size:
391.5KB
Format:
PDF
View/Open
Name:
art41627_am.pdf
Size:
275.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.